
Andrew T Parsa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11122479/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. Clinical Cancer Research, 2019, 25, 3643-3657.	7.0	128
2	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. Clinical Cancer Research, 2017, 23, 3575-3584.	7.0	78
3	In Reply: Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities. Neurosurgery, 2017, 81, E32-E32.	1.1	Ο
4	Safety and outcomes of preoperative embolization of intracranial hemangioblastomas: A systematic review. Clinical Neurology and Neurosurgery, 2016, 150, 143-151.	1.4	35
5	Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series. World Neurosurgery, 2016, 95, 368-374.	1.3	26
6	Immunomonitoring in glioma immunotherapy: current status and future perspectives. Journal of Neuro-Oncology, 2016, 127, 1-13.	2.9	20
7	Role of preoperative embolization for intradural spinal hemangioblastomas. Journal of Clinical Neuroscience, 2016, 24, 83-87.	1.5	15
8	The limited capacity of malignant glioma-derived exosomes to suppress peripheral immune effectors. Journal of Neuroimmunology, 2016, 290, 103-108.	2.3	25
9	Predictors of recurrence in the management of chordoid meningioma. Journal of Neuro-Oncology, 2016, 126, 107-116.	2.9	24
10	Pigmented villonodular synovitis of the temporomandibular joint with intracranial extension: A case series and systematic review. Head and Neck, 2015, 37, 1213-1224.	2.0	46
11	Proportional Upregulation of CD97 Isoforms in Glioblastoma and Glioblastoma-Derived Brain Tumor Initiating Cells. PLoS ONE, 2015, 10, e0111532.	2.5	19
12	Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities. Neurosurgery, 2015, 76, 179-186.	1.1	72
13	Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor Â. Neuro-Oncology, 2015, 17, 832-842.	1.2	18
14	Risk factors for postoperative cerebrospinal fluid leak and meningitis after expanded endoscopic endonasal surgery. Journal of Clinical Neuroscience, 2015, 22, 48-54.	1.5	129
15	Management of central nervous system teratoma. Journal of Clinical Neuroscience, 2015, 22, 98-104.	1.5	17
16	Tumor-to-tumor metastasis: Breast carcinoma to meningioma. Journal of Clinical Neuroscience, 2015, 22, 268-274.	1.5	29
17	Heat shock protein vaccines against glioblastoma: from bench to bedside. Journal of Neuro-Oncology, 2015, 123, 441-448.	2.9	63
18	Quality Improvement in Neurosurgery. Neurosurgery Clinics of North America, 2015, 26, xiii-xiv.	1.7	8

#	Article	IF	CITATIONS
19	The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. Journal of Clinical Neuroscience, 2015, 22, 1964-1968.	1.5	61
20	Prognostic factors for recurrence and complications in the surgical management of primary chordoid gliomas: A systematic review of literature. Clinical Neurology and Neurosurgery, 2015, 138, 129-136.	1.4	32
21	Association of tumor location, extent of resection, and neurofibromatosis status with clinical outcomes for 221 spinal nerve sheath tumors. Neurosurgical Focus, 2015, 39, E5.	2.3	43
22	Vaccine Therapies in Malignant Glioma. Current Neurology and Neuroscience Reports, 2015, 15, 508.	4.2	21
23	The current trend of administering a patient-generated index in the oncological setting: a systematic review. Oncology Reviews, 2014, 8, 245.	1.8	11
24	The role of epidermal growth factor-like module containing mucin-like hormone receptor 2 in human cancers. Oncology Reviews, 2014, 8, 242.	1.8	5
25	PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. Immunotherapy, 2014, 6, 737-753.	2.0	17
26	Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro-Oncology, 2014, 16, 628-636.	1.2	166
27	Surgery is cost-effective treatment for young patients with vestibular schwannomas: decision tree modeling of surgery, radiation, and observation. Neurosurgical Focus, 2014, 37, E8.	2.3	32
28	Intrameningioma Metastasis of Breast Carcinoma. Rare Tumors, 2014, 6, 49-52.	0.6	14
29	Medical errors in neurosurgery. , 2014, 5, 435.		24
30	GLIOMAS PROMOTE INDUCTION OF B7-H1/PD-L1 EXPRESSION ON MONOCYTES: CLINICAL EVIDENCE OF AN IMMUNOSUPPRESSIVE MECHANISM THAT CAN BE TARGETED WITH ANTIBODY BLOCKADE. Neuro-Oncology, 2014, 16, iii41-iii41.	1.2	1
31	Surgical outcomes in spinal cord ependymomas and the importance of extent of resection in children and young adults. Journal of Neurosurgery: Pediatrics, 2014, 13, 393-399.	1.3	39
32	Frequency and predictors of complications in neurological surgery: national trends from 2006 to 2011. Journal of Neurosurgery, 2014, 120, 736-745.	1.6	155
33	Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial. Neuro-Oncology, 2014, 16, 758-759.	1.2	18
34	Management of Planum/Olfactory Meningiomas: Predicting Symptoms and Postoperative Complications. World Neurosurgery, 2014, 82, 1216-1223.	1.3	15
35	Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients. Journal of Clinical Neuroscience, 2014, 21, 2129-2134.	1.5	12
36	Prognosis by tumor location in adults with intracranial ependymomas. Journal of Clinical Neuroscience, 2014, 21, 2096-2101.	1.5	41

#	Article	IF	CITATIONS
37	Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells. Journal of Translational Medicine, 2014, 12, 345.	4.4	21
38	NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with <i>EGFR</i> Amplification. Molecular Cancer Therapeutics, 2014, 13, 2919-2929.	4.1	17
39	Surgical risk factors for post-operative pneumonia following meningioma resection. Clinical Neurology and Neurosurgery, 2014, 118, 76-79.	1.4	21
40	Systematic Review of Protein Biomarkers of Invasive Behavior in Glioblastoma. Molecular Neurobiology, 2014, 49, 1212-1244.	4.0	28
41	Intraventricular neurocytomas: A systematic review of stereotactic radiosurgery and fractionated conventional radiotherapy for residual or recurrent tumors. Clinical Neurology and Neurosurgery, 2014, 117, 55-64.	1.4	29
42	Complement anaphylatoxins as immune regulators in cancer. Cancer Medicine, 2014, 3, 747-758.	2.8	41
43	Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro-Oncology, 2014, 16, 274-279.	1.2	188
44	Anticonvulsant prophylaxis for brain tumor surgery: determining the current best available evidence. Journal of Neurosurgery, 2014, 121, 1139-1147.	1.6	52
45	Towards a hypermodern theory of meningioma surgery. Clinical Neurology and Neurosurgery, 2014, 126, 69-75.	1.4	3
46	Vaccine therapies for patients with glioblastoma. Journal of Neuro-Oncology, 2014, 119, 531-546.	2.9	32
47	Pleomorphic xanthoastrocytomas: Institutional experience of 18 patients. Journal of Clinical Neuroscience, 2014, 21, 1767-1772.	1.5	21
48	What clinical factors predict the incidence of deep venous thrombosis and pulmonary embolism in neurosurgical patients?. Journal of Neurosurgery, 2014, 121, 908-918.	1.6	63
49	Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12823-12828.	7.1	146
50	Immunocompetent murine models for the study of glioblastoma immunotherapy. Journal of Translational Medicine, 2014, 12, 107.	4.4	175
51	Principles of Surgery for Malignant Astrocytomas. Seminars in Oncology, 2014, 41, 523-531.	2.2	4
52	Fractionated radiation therapy for vestibular schwannoma. Journal of Clinical Neuroscience, 2014, 21, 1083-1088.	1.5	13
53	Facial neuroma masquerading as acoustic neuroma. Journal of Clinical Neuroscience, 2014, 21, 1817-1818.	1.5	2
54	Use of thrombin-based hemostatic matrix during meningioma resection: A potential risk factor for perioperative thromboembolic events. Clinical Neurology and Neurosurgery, 2014, 119, 116-120.	1.4	22

#	Article	IF	CITATIONS
55	Modern treatment of 84 newly diagnosed craniopharyngiomas. Journal of Clinical Neuroscience, 2014, 21, 1558-1566.	1.5	17
56	Spinal ependymomas: Benefits of extent of resection for different histological grades. Journal of Clinical Neuroscience, 2013, 20, 1390-1397.	1.5	39
57	Surgical outcomes in choroid plexus papillomas: an institutional experience. Journal of Neuro-Oncology, 2013, 113, 117-125.	2.9	29
58	Na+/K+-ATPase Â2-subunit (AMOG) expression abrogates invasion of glioblastoma-derived brain tumor-initiating cells. Neuro-Oncology, 2013, 15, 1518-1531.	1.2	30
59	Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein. Clinical Cancer Research, 2013, 19, 205-214.	7.0	158
60	Disseminated progression of glioblastoma after treatment with bevacizumab. Clinical Neurology and Neurosurgery, 2013, 115, 1795-1801.	1.4	19
61	Falcine and parasagittal chondrosarcomas. Journal of Clinical Neuroscience, 2013, 20, 1232-1236.	1.5	9
62	G-protein coupled receptor kinase (GRK)-5 regulates proliferation of glioblastoma-derived stem cells. Journal of Clinical Neuroscience, 2013, 20, 1014-1018.	1.5	32
63	The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma. Journal of Clinical Neuroscience, 2013, 20, 281-286.	1.5	51
64	Skull Base Chondrosarcoma. Neurosurgery Clinics of North America, 2013, 24, 89-96.	1.7	69
65	Modern surgical outcomes following surgery for sphenoid wing meningiomas. Journal of Neurosurgery, 2013, 119, 86-93.	1.6	40
66	Prognosis by tumor location in adults with spinal ependymomas. Journal of Neurosurgery: Spine, 2013, 18, 226-235.	1.7	59
67	A Spheroid Weighted-Axis Converter of Vestibular Schwannoma Size. Otolaryngology - Head and Neck Surgery, 2013, 148, 108-114.	1.9	6
68	Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas. Neuro-Oncology, 2013, 15, 208-215.	1.2	70
69	Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages. Clinical Cancer Research, 2013, 19, 3165-3175.	7.0	393
70	Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis. Neuro-Oncology, 2013, 15, 255-267.	1.2	78
71	Pathology of Spinal Ependymomas. Neurosurgery, 2013, 73, 247-255.	1.1	50
72	Mannose-Binding Lectin 2 Gene and Risk of Adult Glioma. PLoS ONE, 2013, 8, e61117.	2.5	7

#	Article	IF	CITATIONS
73	Overexpression of CD97 Confers an Invasive Phenotype in Glioblastoma Cells and Is Associated with Decreased Survival of Glioblastoma Patients. PLoS ONE, 2013, 8, e62765.	2.5	44
74	Association of Morbidity with Extent of Resection and Cavernous Sinus Invasion in Sphenoid Wing Meningiomas. Skull Base, 2012, 21, e5-e5.	0.4	1
75	Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro-Oncology, 2012, 14, 942-954.	1.2	183
76	Neuroanatomical correlation of the House-Brackmann grading system in the microsurgical treatment of vestibular schwannoma. Neurosurgical Focus, 2012, 33, E7.	2.3	16
77	Association of Morbidity with Extent of Resection and Cavernous Sinus Invasion in Sphenoid Wing Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2012, 73, 076-083.	0.8	12
78	Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro-Oncology, 2012, 14, 584-595.	1.2	120
79	Neurosurgical Management and Prognosis of Patients With Glioblastoma That Progresses During Bevacizumab Treatment. Neurosurgery, 2012, 70, 361-370.	1.1	60
80	Reporting Standard Compliance in Publications of Vestibular Schwannoma Patients Treated With Microsurgery. Otology and Neurotology, 2012, 33, 648-650.	1.3	6
81	Immunotherapy for Glioma. Neurosurgery Clinics of North America, 2012, 23, 357-370.	1.7	36
82	Impact of extent of resection for recurrent glioblastoma on overall survival. Journal of Neurosurgery, 2012, 117, 1032-1038.	1.6	370
83	The effect of the 2003 Consensus Reporting Standards on publications describing patients with vestibular schwannoma treated with stereotactic radiosurgery. Journal of Clinical Neuroscience, 2012, 19, 1144-1147.	1.5	7
84	Treatment-related morbidity and the management of pediatric craniopharyngioma. Journal of Neurosurgery: Pediatrics, 2012, 10, 293-301.	1.3	77
85	Intracranial hemangiopericytoma. Cancer, 2012, 118, 1628-1636.	4.1	128
86	Stereotactic radiosurgery for benign meningiomas. Journal of Neuro-Oncology, 2012, 107, 13-20.	2.9	65
87	Heat shock protein–peptide complex in the treatment of glioblastoma. Expert Review of Vaccines, 2011, 10, 721-731.	4.4	23
88	Preface. Neurosurgery Clinics of North America, 2011, 22, xi.	1.7	1
89	Functional mapping–guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Journal of Neurosurgery, 2011, 114, 566-573.	1.6	253
90	An extent of resection threshold for newly diagnosed glioblastomas. Journal of Neurosurgery, 2011, 115, 3-8.	1.6	1,323

#	Article	IF	CITATIONS
91	The molecular pathology of central neurocytomas. Journal of Clinical Neuroscience, 2011, 18, 1-6.	1.5	22
92	Clinical and surgical considerations for cerebellopontine angle meningiomas. Journal of Clinical Neuroscience, 2011, 18, 755-759.	1.5	27
93	Signaling pathways in cranial chondrosarcoma: potential molecular targets for directed chemotherapy. Journal of Clinical Neuroscience, 2011, 18, 881-885.	1.5	18
94	Awake far lateral craniotomy for resection of foramen magnum meningioma in a patient with tenuous motor and somatosensory evoked potentials. Journal of Clinical Neuroscience, 2011, 18, 1254-1256.	1.5	13
95	Implications of Cystic Features in Vestibular Schwannomas of Patients Undergoing Microsurgical Resection. Neurosurgery, 2011, 68, 874-880.	1.1	33
96	Embolization of Skull Base Meningiomas and Feeding Vessels Arising From the Internal Carotid Circulation. Neurosurgery, 2011, 68, 162-169.	1.1	59
97	Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma. Journal of Neuro-Oncology, 2011, 101, 463-476.	2.9	109
98	Factors associated with preservation of facial nerve function after surgical resection of vestibular schwannoma. Journal of Neuro-Oncology, 2011, 102, 281-286.	2.9	80
99	Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma. Journal of Neuro-Oncology, 2011, 105, 165-171.	2.9	20
100	Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma. Journal of Neuro-Oncology, 2011, 105, 317-323.	2.9	5
101	Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer, 2011, 117, 1272-1278.	4.1	164
102	Beyond audiofacial morbidity after vestibular schwannoma surgery. Journal of Neurosurgery, 2011, 114, 367-374.	1.6	82
103	Impact of bevacizumab chemotherapy on craniotomy wound healing. Journal of Neurosurgery, 2011, 114, 1609-1616.	1.6	93
104	Postoperative seizures following the resection of convexity meningiomas: are prophylactic anticonvulsants indicated?. Journal of Neurosurgery, 2011, 114, 705-709.	1.6	70
105	Results with judicious modern neurosurgical management of parasagittal and falcine meningiomas. Journal of Neurosurgery, 2011, 114, 731-737.	1.6	58
106	Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. Journal of Neurosurgery, 2011, 115, 505-511.	1.6	102
107	Intratumoral hemorrhage and fibrosis in vestibular schwannoma: a possible mechanism for hearing loss. Journal of Neurosurgery, 2011, 114, 386-393.	1.6	44
108	A prospective study of hearing preservation in untreated vestibular schwannomas. Journal of Neurosurgery, 2011, 114, 381-385.	1.6	77

#	Article	IF	CITATIONS
109	Extent of resection and the long-term durability of vestibular schwannoma surgery. Journal of Neurosurgery, 2011, 114, 1218-1223.	1.6	85
110	Risk factors for the development of serious medical complications after resection of meningiomas. Journal of Neurosurgery, 2011, 114, 697-704.	1.6	53
111	Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. Journal of Neurosurgery, 2011, 114, 359-366.	1.6	41
112	The molecular biology and novel treatments of vestibular schwannomas. Journal of Neurosurgery, 2011, 115, 906-914.	1.6	58
113	A Critical Evaluation of Vestibular Schwannoma Surgery for Patients Younger Than 40 Years of Age. Neurosurgery, 2010, 67, 1646-1654.	1.1	18
114	Mapping Clinical Outcomes Expectations to Treatment Decisions. Otology and Neurotology, 2010, 31, 284-293.	1.3	26
115	EMR-3. NeuroReport, 2010, 21, 1018-1022.	1.2	22
116	The complement cascade as a mediator of tissue growth and regeneration. Inflammation Research, 2010, 59, 897-905.	4.0	109
117	Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. Journal of Neuro-Oncology, 2010, 98, 101-108.	2.9	68
118	Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. Journal of Neuro-Oncology, 2010, 96, 313-320.	2.9	128
119	Surgical Technique of Temporary Arterial Occlusion in the Operative Management of Spinal Hemangioblastomas. World Neurosurgery, 2010, 74, 200-205.	1.3	22
120	Ubiquitin-Specific Protease 8 Links the PTEN-Akt-AIP4 Pathway to the Control of FLIPS Stability and TRAIL Sensitivity in Glioblastoma Multiforme. Cancer Research, 2010, 70, 5046-5053.	0.9	63
121	The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. Journal of Neurosurgery, 2010, 112, 163-167.	1.6	168
122	A comprehensive analysis of hearing preservation after radiosurgery for vestibular schwannoma. Journal of Neurosurgery, 2010, 112, 851-859.	1.6	142
123	Cancer and the Complement Cascade. Molecular Cancer Research, 2010, 8, 1453-1465.	3.4	206
124	Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurgical Focus, 2010, 28, E5.	2.3	163
125	Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients. Journal of Neurosurgery, 2010, 112, 990-996.	1.6	49
126	Posttreatment prognosis of patients with esthesioneuroblastoma. Journal of Neurosurgery, 2010, 113, 340-351.	1.6	87

#	Article	IF	CITATIONS
127	Secondary gliosarcoma: a review of clinical features and pathological diagnosis. Journal of Neurosurgery, 2010, 112, 26-32.	1.6	49
128	Factors affecting outcome following treatment of patients with cavernous sinus meningiomas. Journal of Neurosurgery, 2010, 113, 1087-1092.	1.6	67
129	TGF-Â downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-Oncology, 2010, 12, 7-13.	1.2	267
130	Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. Journal of Neurosurgery, 2010, 113, 202-209.	1.6	134
131	Cranial Chondrosarcoma and Recurrence. Skull Base, 2010, 20, 149-156.	0.4	89
132	Glioblastoma Multiforme Regional Genetic and Cellular Expression Patterns: Influence on Anatomic and Physiologic MR Imaging. Radiology, 2010, 254, 564-576.	7.3	148
133	Treatment decision making based on the published natural history and growth rate of small meningiomas. Journal of Neurosurgery, 2010, 113, 1036-1042.	1.6	121
134	The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. Journal of Neurosurgery, 2010, 113, 1029-1035.	1.6	244
135	Monitoring Immune Responses After Glioma Vaccine Immunotherapy. Neurosurgery Clinics of North America, 2010, 21, 195-199.	1.7	6
136	Heat Shock Proteins in Glioblastomas. Neurosurgery Clinics of North America, 2010, 21, 111-123.	1.7	16
137	Predictors of mortality following treatment of intracranial hemangiopericytoma. Journal of Neurosurgery, 2010, 113, 333-339.	1.6	108
138	The role of microglia in central nervous system immunity and glioma immunology. Journal of Clinical Neuroscience, 2010, 17, 6-10.	1.5	301
139	Hearing preservation rates after microsurgical resection of vestibular schwannoma. Journal of Clinical Neuroscience, 2010, 17, 1126-1129.	1.5	67
140	CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. Journal of Clinical Neuroscience, 2010, 17, 1381-1385.	1.5	147
141	Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. Journal of Clinical Neuroscience, 2010, 17, 1543-1547.	1.5	30
142	Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy. Neurosurgery Clinics of North America, 2010, 21, 181-186.	1.7	39
143	Preservation of facial nerve function after resection of vestibular schwannoma. British Journal of Neurosurgery, 2010, 24, 666-671.	0.8	75
144	Intramedullary Spinal Cord Tumors. Pediatric Oncology, 2010, , 187-204.	0.5	2

#	Article	IF	CITATIONS
145	A Novel PTEN-Dependent Link to Ubiquitination Controls FLIPS Stability and TRAIL Sensitivity in Glioblastoma Multiforme. Cancer Research, 2009, 69, 7911-7916.	0.9	44
146	Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. Journal of Clinical Oncology, 2009, 27, 579-584.	1.6	354
147	Flow cytometry and in vitro analysis of human glioma–associated macrophages. Journal of Neurosurgery, 2009, 110, 572-582.	1.6	150
148	Non-audiofacial morbidity after Gamma Knife surgery for vestibular schwannoma. Neurosurgical Focus, 2009, 27, E4.	2.3	54
149	Radiobiology of vestibular schwannomas: mechanisms of radioresistance and potential targets for therapeutic sensitization. Neurosurgical Focus, 2009, 27, E2.	2.3	37
150	Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. Radiology, 2009, 253, 486-496.	7.3	365
151	Facial nerve preservation after vestibular schwannoma Gamma Knife radiosurgery. Journal of Neuro-Oncology, 2009, 93, 41-48.	2.9	126
152	Hearing preservation after stereotactic radiosurgery for vestibular schwannoma: A systematic review. Journal of Clinical Neuroscience, 2009, 16, 742-747.	1.5	132
153	A systematic review of intracranial chondrosarcoma and survival. Journal of Clinical Neuroscience, 2009, 16, 1547-1551.	1.5	127
154	Immunological considerations of modern animal models of malignant primary brain tumors. Journal of Translational Medicine, 2009, 7, 84.	4.4	21
155	Honokiol-mediated Inhibition of PI3K/mTOR Pathway. Journal of Immunotherapy, 2009, 32, 585-592.	2.4	77
156	Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. NeuroReport, 2009, 20, 1597-1602.	1.2	37
157	AANS/CNS section on tumor satellite meeting. Journal of Neuro-Oncology, 2008, 87, 195-195.	2.9	0
158	Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. Journal of Neurosurgery, 2008, 109, 817-824.	1.6	226
159	Endoscopic Reconstruction of Skull Base Defects with the Nasal Septal Flap. Skull Base, 2008, 18, 385-394.	0.4	87
160	FLUCTUATING RESPONSE OF A CYSTIC VESTIBULAR SCHWANNOMA TO RADIOSURGERY. Neurosurgery, 2008, 62, E1164-E1165.	1.1	34
161	Modified Paramedian Transpedicular Approach and Spinal Reconstruction for Intradural Tumors of the Cervical and Cervicothoracic Spine. Spine, 2007, 32, E203-E210.	2.0	32
162	LACK OF B7 EXPRESSION, NOT HUMAN LEUKOCYTE ANTIGEN EXPRESSION, FACILITATES IMMUNE EVASION BY HUMAN MALIGNANT GLIOMAS. Neurosurgery, 2007, 60, 1129-1136.	1.1	37

Andrew T Parsa

#	Article	IF	CITATIONS
163	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine, 2007, 13, 84-88.	30.7	1,177
164	Clinical Management of Intramedullary Spinal Ependymomas in Adults. Neurosurgery Clinics of North America, 2006, 17, 21-27.	1.7	25
165	Pathologic and Epidemiologic Findings of Intramedullary Spinal Cord Tumors. Neurosurgery Clinics of North America, 2006, 17, 7-11.	1.7	46
166	Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide. Molecular Cancer Therapeutics, 2006, 5, 20-28.	4.1	37
167	Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. Journal of Neurosurgery, 2005, 103, 428-438.	1.6	155
168	Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. Journal of Neurosurgery, 2005, 102, 622-628.	1.6	108
169	Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection correlate with postoperative motor function. Neurosurgery, 2005, 56, 982-93; discussion 982-93.	1.1	138
170	Intramedullary spinal cord tumors: molecular insights and surgical innovation. Clinical Neurosurgery, 2005, 52, 76-84.	0.2	28
171	Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature, 2004, 427, 740-744.	27.8	1,231
172	Spinal Cord and Intradural-Extraparenchymal Spinal Tumors: Current Best Care Practices and Strategies. Journal of Neuro-Oncology, 2004, 69, 291-318.	2.9	132
173	Cooperative translational control of gene expression by Ras and Akt in cancer. Trends in Molecular Medicine, 2004, 10, 607-613.	6.7	51
174	Title is missing!. Journal of Neuro-Oncology, 2003, 64, 77-87.	2.9	1
175	Autologous adjuvant linked fibroblasts induce anti-glioma immunity: implications for development of a glioma vaccine. Journal of Neuro-Oncology, 2003, 64, 77-87.	2.9	5
176	Intraventricular neurocytomas. Neurosurgery Clinics of North America, 2003, 14, 483-508.	1.7	26
177	Changes in the Immunologic Phenotype of Human Malignant Glioma Cells after Passaging in Vitro. Clinical Immunology, 2002, 102, 84-95.	3.2	39
178	Radiosurgery for the Treatment of Recurrent Central Neurocytomas. Neurosurgery, 2001, 48, 1231-1238.	1.1	60
179	Limitations of the C6/Wistar Rat Intracerebral Glioma Model: Implications for Evaluating Immunotherapy. Neurosurgery, 2000, 47, 993-1000.	1.1	84
180	Tissue Distribution and Antitumor Activity of Topotecan Delivered by Intracerebral Clysis in a Rat Glioma Model. Neurosurgery, 2000, 47, 1391-1399.	1.1	34

#	Article	IF	CITATIONS
181	Intracerebral Clysis in a Rat Glioma Model. Neurosurgery, 2000, 46, 683-691.	1.1	87
182	Tissue Distribution and Antitumor Activity of Topotecan Delivered by Intracerebral Clysis in a Rat Glioma Model. Neurosurgery, 2000, 47, 1391-1399.	1.1	84